Compositions and assays to detect influenza virus A and B nucleic acids
View Patent ↗Methods for detecting influenza virus A and influenza virus B nucleic acids in biological samples by using in vitro amplification and detection are disclosed. Compositions that are target-specific nucleic acid sequences and kits comprising target-specific nucleic acid oligomers for amplifying in vitro influenza virus A or influenza virus B nucleic acid and detecting amplified nucleic acid sequences are disclosed.
1. A composition comprising at least two isolated nucleic acid oligomers specific for influenza virus B consisting of SEQ ID NO:39 and SEQ ID NO:44, or completely complementary sequences to SEQ ID NO:39 and SEQ ID NO:44.
2. The composition of claim 1 , wherein the two nucleic acid oligomers include an oligomer consisting of SEQ ID NO:44.
3. The composition of claim 1 , that further includes at least one oligomer consisting of SEQ ID NO:48.
4. The composition of claim 1 , wherein the at least two nucleic acid oligomers specific for influenza virus B are in the form of a kit.
5. A method of detecting nucleic acid of influenza virus B in a sample, comprising the steps of:
providing a sample containing influenza virus B nucleic acid;
amplifying a target sequence in the influenza virus B nucleic acid contained in the sample by using a nucleic acid polymerase and at least two isolated nucleic acid oligomers consisting of the sequences of SEQ ID Nos. 39 and 44, or the complete complements of the sequences consisting of SEQ ID Nos. 39 and 44 in vitro to produce an amplified product under substantially isothermal conditions, and
detecting the amplified product, thereby detecting the presence of influenza virus B in the sample.
6. The method of claim 5 , wherein amplifying the target sequence in the influenza virus B nucleic acid uses at least one oligomer consisting of the sequence of SEQ ID NO:39 and one oligomer consisting of the sequence of SEQ ID NO:44.
7. The method of claim 5 , wherein the detecting step uses at least one probe consisting of SEQ ID NO:48 that includes at least one 2′-methoxy RNA group to detect the amplified product of the target sequence of influenza virus B.
8. The method of claim 5 , further including the steps of providing an internal control oligomer, amplifying a target sequence contained in the internal control oligomer, and detecting the amplified product made from the internal control oligomer, thereby indicating that the amplifying and detecting steps of the method were properly performed.
9. The method of claim 5 , further including a step of isolating the influenza virus B nucleic acid from the sample before the amplifying step.
10. The method of claim 5 , wherein the target sequence is contained in the sequence consisting of SEQ ID NO:32, the complete complement of the sequence consisting of SEQ ID NO:32, the RNA equivalent of the sequence consisting of SEQ ID NO:32, or the RNA equivalent of the complete complement of the sequence consisting of SEQ ID NO:32.
11. The method of claim 5 , wherein the detecting step uses a probe that detects the amplified product in a homogeneous assay system.
12. A composition comprising at least two isolated nucleic acid oligomers specific for influenza virus B wherein one oligomer has a target hybridizing sequence that is from 19 to 21 nucleotides in length and contains a sequences consisting essentially of SEQ ID NO:42, the complement and/or RNA equivalent thereof and, optionally, contains at least one 2′ methoxy RNA group or at least one LNA; and wherein a second oligomer has a sequence that is from 19 to 22 nucleotides in length and contains a sequence consisting essentially of SEQ ID NO:44, the complement and/or RNA equivalent thereof and, optionally, contains at least one 2′ methoxy RNA group or at least one LNA.
13. The composition of claim 12 , wherein a third oligomer has a sequence consisting of SEQ ID NO:48, the completely complementary sequence of SEQ ID NO:48 and, optionally, at least one detectable label joined directly or indirectly to the oligomer sequence.
14. The composition of claim 13 , wherein the label is detectable in a homogenous assay system.
15. The composition of claim 13 , wherein the label is an acridinium ester compound.
16. The composition of claim 12 , wherein 5′ positions 1 to 3 of the SEQ ID NO:44 sequence are in an LNA conformation.
17. The composition of claim 12 , wherein 5′ positions 1 to 4 of the SEQ ID NO:44 sequence are in an LNA conformation.
18. The composition of claim 12 , wherein the at least two nucleic acid oligomers specific for influenza virus B are in the form of a kit.
19. A method of detecting nucleic acid of influenza virus B in a sample, comprising the steps of:
providing a sample containing influenza virus B nucleic acid;
amplifying a target sequence in the influenza virus B nucleic acid contained in the sample by using a nucleic acid polymerase and at least two isolated nucleic acid amplification oligomers, wherein the at least two nucleic acid amplification oligomers includes an amplification oligomer 19 to 21 nucleotides in length consisting essentially of the nucleotide target hybridizing sequences of SEQ ID NO:42, the complement and/or RNA equivalent thereof and, optionally, contains at least one 2′ methoxy RNA group or at least one LNA, and wherein the at least two nucleic acid amplification oligomers includes an amplification oligomer 19 to 22 nucleotides in length consisting essentially of the nucleotide sequences of SEQ ID NO:44, the complement and/or RNA equivalent thereof and, optionally, contains at least one 2′ methoxy RNA group or at least one LNA, in vitro to produce an amplified product under substantially isothermal conditions, and
detecting the amplified product, thereby detecting the presence of influenza virus B in the sample.
20. The method of claim 19 , wherein the detecting step uses at least one probe consisting of SEQ ID NO:48 that includes at least one 2′-methoxy RNA group to detect the amplified product of the target sequence of influenza virus B.
21. The method of claim 19 , further including the steps of providing an internal control oligomer, amplifying a target sequence contained in the internal control oligomer, and detecting the amplified product made from the internal control oligomer, thereby indicating that the amplifying and detecting steps of the method were properly performed.
22. The method of claim 19 , further including a step of isolating the influenza virus B nucleic acid from the sample before the amplifying step.
23. The method of claim 19 , wherein the target sequence is contained in the sequence consisting of SEQ ID NO:32, the complete complement of the sequence consisting of SEQ ID NO:32, the RNA equivalent of the sequence consisting of SEQ ID NO:32, or the RNA equivalent of the complete complement of the sequence consisting of SEQ ID NO:32.
24. The method of claim 19 , wherein 5′ positions 1 to 3 of the oligomer consisting of SEQ ID NO:44 are in a locked nucleic acid (LNA) conformation.
25. The method of claim 19 , wherein 5′ positions 1 to 4 of the oligomer consisting of SEQ ID NO:44 are in a locked nucleic acid (LNA) conformation.
26. The method of claim 19 , wherein the detecting step uses a probe that detects the amplified product in a homogeneous assay system.
27. The method of claim 19 , wherein the detecting step uses at least one probe consisting of SEQ ID NO:48 that includes at least one 2′-methoxy RNA group, at least one detectable label or both, to detect the amplified product of the target sequence of influenza virus B.
28. The method of claim 27 wherein the detectable label is an acridinium ester compound.
29. : The method of claim 19 , wherein the amplification oligomer 19 to 21 nucleotides in length consisting essentially of the nucleotide target hybridizing sequences of SEQ ID NO:42, the complement and/or RNA equivalent thereof and, optionally, contains at least one 2′ methoxy RNA group or at least one LNA, further includes a 5′ promoter sequence that is SEQ ID NO19 or SEQ ID NO:20.
30. The composition of claim 12 , wherein the oligomer that has a target hybridizing sequence that is from 19 to 21 nucleotides in length and contains a sequences consisting essentially of SEQ ID NO:42 , the complement and/or RNA equivalent thereof and, optionally, contains at least one 2′ methoxy RNA group or at least one LNA, further includes a 5′ promoter sequence that is SEQ ID NO19 or SEQ ID NO:20.